Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| ID | DOID:4007 |
| Name | bladder carcinoma |
| Definition | A urinary bladder cancer that has_material_basis_in abnormally proliferating cells derives_from epithelial cells. |
| Source | DiseaseOntology.org |
| Alt Ids | |
| Path | disease disease of cellular proliferation cancer organ system cancer urinary system cancer urinary bladder cancer bladder carcinoma |
| Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
|---|---|---|---|---|
| TSC1 E636fs | Everolimus | bladder carcinoma | sensitive | detail... |
| FGFR3 wild-type | Vofatamab | bladder carcinoma | sensitive | detail... |
| FGFR3 S249C | Vofatamab | bladder carcinoma | sensitive | detail... |
| TSC1 mutant | Everolimus | bladder carcinoma | sensitive | detail... |
| FGFR3 S249C | CPL304110 | bladder carcinoma | sensitive | detail... |
| FGFR3 fusion FGFR3 amp | CPL304110 | bladder carcinoma | sensitive | detail... |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT00942331 | Phase III | Bevacizumab + Cisplatin + Gemcitabine Cisplatin + Gemcitabine | Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer | Completed | USA | 1 |
| NCT01259063 | Phase Ib/II | Everolimus + Gemcitabine | RAD001 and Intravesical Gemcitabine in BCG-Refractory Primary or Secondary Carcinoma In Situ of the Bladder | Completed | USA | 0 |
| NCT01366144 | Phase I | Paclitaxel Veliparib Carboplatin | Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction | Active, not recruiting | USA | 0 |
| NCT01391143 | Phase I | Enoblituzumab | Safety Study of MGA271 in Refractory Cancer | Completed | USA | 0 |
| NCT01688999 | Phase II | Cabozantinib | Cabozantinib for Advanced Urothelial Cancer | Completed | USA | 0 |
| NCT01938573 | Phase Ib/II | Cisplatin + Gemcitabine + Sirolimus | Sirolimus, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Bladder Cancer | Completed | USA | 0 |
| NCT02169284 | Phase II | Erlotinib | Erlotinib Hydrochloride in Treating Patients With Bladder Cancer Undergoing Surgery | Terminated | USA | 0 |
| NCT02432963 | Phase I | MVAp53 + Pembrolizumab | Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy | Active, not recruiting | USA | 0 |
| NCT02444793 | Phase I | Mogamulizumab + Utomilumab | A Study of PF-05082566 In Combination With Mogamulizumab In Patients With Advanced Solid Tumors | Terminated | USA | 0 |
| NCT02636036 | Phase I | Enadenotucirev + Pembrolizumab | Study of Enadenotucirev and Pembrolizumab in Subjects With Metastatic or Advanced Epithelial Tumors | Completed | USA | 0 |
| NCT02723955 | Phase I | GSK3359609 GSK3359609 + Pembrolizumab | Dose Escalation and Expansion Study of GSK3359609 in Subjects With Selected Advanced Solid Tumors (INDUCE-1) | Completed | USA | NLD | ITA | FRA | ESP | CAN | AUS | 2 |
| NCT03171025 | Phase II | Nivolumab | Adjuvant Nivolumab Following Chemo-Radiation in Localized Muscle-Invasive Bladder Cancer (NEXT) | Active, not recruiting | USA | 0 |
| NCT03319745 | Phase II | Pembrolizumab | A Window of Opportunity Study of Pembrolizumab in Patients With Bladder Cancer Undergoing Radical Cystectomy | Completed | USA | 0 |
| NCT03430895 | Phase II | Durvalumab + Tremelimumab | Evaluating Immune Therapy, Durvalumab (MEDI4736) With Tremelimumab for Metastatic, Non-transitional Cell Carcinoma of the Urinary Tract | Completed | USA | 0 |
| NCT03693014 | Phase II | A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors | Active, not recruiting | USA | 0 | |
| NCT04054752 | Phase I | NT-I7 | Vaccine Response With NT-I7 | Withdrawn | USA | 0 |
| NCT06120075 | Phase I | AB801 AB801 + Docetaxel AB801 + Docetaxel + Zimberelimab | A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies (ARC-27) | Recruiting | USA | 0 |
| NCT06444815 | Phase I | VET3-TGI Pembrolizumab + VET3-TGI | A Study of VET3-TGI in Patients With Solid Tumors (STEALTH-001) | Recruiting | USA | 0 |